Clinical Trials
29 trialsThiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
Peking University People's Hospital
Haplo-Cord HSCT for AML/MDS
Fujian Medical University Union Hospital
TBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia
Asan Medical Center
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
First Affiliated Hospital Xi'an Jiaotong University
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
UCAML
Baylor College of Medicine
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Busulfan and Cyclophosphamide Followed By ALLO BMT
Masonic Cancer Center, University of Minnesota
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
University of Chicago
Stem Cell Transplant for Hematological Malignancy
Masonic Cancer Center, University of Minnesota
THALLO
Baylor College of Medicine
Interfant06
Dutch Childhood Oncology Group
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
University of Miami
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
City of Hope Medical Center
Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas
National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
National Cancer Institute (NCI)
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
University of California, San Francisco
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
OHSU Knight Cancer Institute
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
University of Oklahoma
Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas
St. Jude Children's Research Hospital